<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="17">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160922</url>
  </required_header>
  <id_info>
    <org_study_id>A8081075</org_study_id>
    <nct_id>NCT05160922</nct_id>
  </id_info>
  <brief_title>Crizotinib Continuation Clinical Study</brief_title>
  <official_title>Crizotinib Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Crizotinib Clinical Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this continuation study is to provide continued access to crizotinib treatment&#xD;
      for eligible participants from a current Pfizer sponsored crizotinib clinical study that is&#xD;
      planned to close.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants not previously enrolled or who have discontinued study treatment or safety&#xD;
      follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for&#xD;
      participation in this continuation study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2026</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events leading to permanent discontinuation of study intervention</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Safety data collection in this study will permit further characterization of the safety profile of crizotinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events reported for all participants</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
    <description>Safety data collection in this study will permit further characterization of the safety profile of crizotinib.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>NSCLC</condition>
  <condition>ALCL</condition>
  <condition>IMT</condition>
  <arm_group>
    <arm_group_label>crizotinib</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>crizotinib oral treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>crizotinib</intervention_name>
    <description>crizotinib oral treatment</description>
    <arm_group_label>crizotinib</arm_group_label>
    <other_name>XALKORI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants must meet the following key inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Any participant who is receiving crizotinib and deriving clinical benefit (as&#xD;
             determined by their doctor) in a Crizotinib Study which is planned to close.&#xD;
&#xD;
          2. Participants must agree to follow the reproductive criteria as outlined in protocol.&#xD;
&#xD;
          3. No ongoing Grade ≥3 or intolerable Grade 2 AEs considered to be related to crizotinib&#xD;
             treatment, except for those laboratory eligibility criteria described in Inclusion #4.&#xD;
&#xD;
          4. Adult Participants (≥18 years): Adequate hepatic and bone marrow function. Stable&#xD;
             renal function for at least 14 days.&#xD;
&#xD;
        Pediatric Participants (&lt;18 years): Adequate hepatic and bone marrow function. Stable renal&#xD;
        function for at least 14 days.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Participants with any of the following characteristics/conditions will be excluded:&#xD;
&#xD;
          1. Female participants who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Any medical reason that, in the opinion of the investigator or sponsor, precludes the&#xD;
             participant from inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=A8081075</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 6, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>crizotinib</keyword>
  <keyword>Xalkori</keyword>
  <keyword>Anaplastic Lymphoma Kinase</keyword>
  <keyword>ALK</keyword>
  <keyword>ROS1</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>ALCL</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>IMT</keyword>
  <keyword>inflammatory myofibroblastic tumour</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

